Karyopharm's SENTRY Phase 3 Trial In Myelofibrosis Hits Spleen Volume Reduction Endpoint, Selinexor-Ruxolitinib Combo Shows Near Doubling Of SVR35 Rates And Promising Overall Survival Signal Versus Ruxolitinib

Benzinga Newsdesk www.benzinga.com Positive 95.6%

Neg 0% Neu 0% Pos 95.6%

Comments

No comments yet. Be the first!